SCHEMBL7084680

SCHEMBL7084680

O=c1[nH]c2ccsc2cc1-c1nc2ccccc2[nH]1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.68
FGFR1 P11362 4/20 0.68
PDGFRB P09619 3/20 0.68
NPC1 O15118 9/20 0.52
GBA1 P04062 1/20 0.52
FLT1 P17948 3/20 0.49
RAB9A P51151 9/20 0.49
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 5/20 0.49
HSD17B10 Q99714 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HPGD P15428 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
PKM P14618 2/20 0.49
ABCB11 O95342 1/20 0.49
TP53 P04637 1/20 0.49
GLA P06280 2/20 0.48
LMNA P02545 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7082535 0.82 FGFR1 (0.66) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3503147 0.81 KDR (1.00) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3502017 0.75 KDR (0.72) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3501208 0.75 KDR (0.72) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3502903 0.74 KDR (0.74) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3502748 0.74 KDR (0.66) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3500603 0.74 KDR (0.74) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL4298828 0.74 KDR (0.74) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL3501636 0.74 KDR (0.66) KDRFGFR1PDGFRBNPC1GBA1
SCHEMBL7084245 0.74 FGFR1 (0.74) KDRFGFR1PDGFRBNPC1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1226119-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2003-04-09 EP disclosed
US-6479512-B1 TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. MERCK & CO., INC. 2002-11-12 US disclosed
EP-1226119-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2002-07-31 EP disclosed
WO-2001028993-A2 TYROSINE KINASE INHIBITORS MERCK & CO. INC. (US) 2001-04-26 WO disclosed